The Growing Power of Biotech Monopolies Threatens Affordable Care
The U.S. has worsened the problem by making the 12-year auto-monopoly a key sticking point in its trade negotiations with the Pacific Rim and with Canada and Mexico: demanding that other countries also adopt the same rule, regardless of underlying intellectual property. Those who favor an innovative pharmceutical market should oppose mandatory monopolies for which innovation is absent.
